Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study ; volume:38 ; number:9 ; day:1 ; month:8 ; year:2018 ; pages:853-865 ; date:9.2018
Clinical drug investigation ; 38, Heft 9 (1.8.2018), 853-865, 9.2018
- Urheber
-
Sangroongruangsri, Sermsiri
- Beteiligte Personen und Organisationen
-
Chaikledkaew, Usa
Kumluang, Suthasinee
Wu, Olivia
Geue, Claudia
Ratanapakorn, Tanapat
Leelahavarong, Pattara
Ingsrisawang, Lily
Ruamviboonsuk, Paisan
Taweebanjongsin, Wongsiri
Choovuthayakorn, Janejit
Singalavanija, Apichart
Hanutsaha, Prut
Kulvichit, Kittisak
Ratanapojnard, Thitiporn
Wongsawad, Warapat
Teerawattananon, Yot
SpringerLink (Online service)
- DOI
-
10.1007/s40261-018-0678-5
- URN
-
urn:nbn:de:101:1-2018110521101361704700
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sangroongruangsri, Sermsiri
- Chaikledkaew, Usa
- Kumluang, Suthasinee
- Wu, Olivia
- Geue, Claudia
- Ratanapakorn, Tanapat
- Leelahavarong, Pattara
- Ingsrisawang, Lily
- Ruamviboonsuk, Paisan
- Taweebanjongsin, Wongsiri
- Choovuthayakorn, Janejit
- Singalavanija, Apichart
- Hanutsaha, Prut
- Kulvichit, Kittisak
- Ratanapojnard, Thitiporn
- Wongsawad, Warapat
- Teerawattananon, Yot
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study
Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study
Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study
Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema